UstekinumabformoderatetoseverepsoriasisY.Mengetal.
In?ammationandAutoimmunity.Basel:Springer;2013;dif?cultiesassociatedwithpsoriasis:resultsfromtwo
287–304.Availableat:http://link.springer.com/chapter/phaseIIIclinicaltrials.JEurAcadDermatolVenereol
10.1007/978-3-0348-0522-3_212011;25:851–7.
4DiMeglioP,VillanovaF,NapolitanoLetal.The15IgarashiA,KatoT,KatoM,SongM,NakagawaH;
IL23RA/Gln381allelepromotesIL-23JapaneseUstekinumabStudyG.Ef?cacyandsafetyof
unresponsivenessinhumanmemoryT-helper17cellsustekinumabinJapanesepatientswith
andimpairsTh17responsesinpsoriasispatients.moderate-to-severeplaque-typepsoriasis:long-term
JInvestDermatol2013;133:2381–9.resultsfromaphase2/3clinicaltrial.JDermatol2012;
5LowesMA,RussellCB,MartinDAetal.TheIL-23/T1739:242–2.
pathogenicaxisinpsoriasisisampli?edbykeratinocyte16KimballAB,PappKA,Was?Yetal.Long-termef?cacy
responses.TrendsImmunol2013;34:174–81.ofustekinumabinpatientswithmoderate-to-severe
6ReichK,LangleyRG,LebwohlMetal.Cardiovascularpsoriasistreatedforupto5yearsinthePHOENIX1
safetyofustekinumabinpatientswithmoderatetostudy.JEurAcadDermatolVenereol2013;27:1535–45.
severepsoriasis:resultsofintegratedanalysesofdata17KruegerGG,LangleyRG,LeonardiCetal.Ahuman
fromphaseIIandIIIclinicalstudies.BrJDermatol2011;interleukin-12/23monoclonalantibodyforthetreatment
164:862–72.ofpsoriasis.NewEnglJMed2007;356:580–2.
7HsuS,PappKA,LebwohlMGetal.Consensusguidelines18LebwohlM,LeonardiC,Grif?thsCEetal.Long-term
forthemanagementofplaquepsoriasis.ArchDermatolsafetyexperienceofustekinumabinpatientswith
2012;148:95.moderate-to-severepsoriasis(PartIofII):resultsfrom
8TanJY,LiS,YangKetal.Ustekinumab,ahumananalysesofgeneralsafetyparametersfrompooledPhase
interleukin-12/23monoclonalantibody,inpatientswith2and3clinicaltrials.JAmAcadDermatol2012;66:
psoriasis:ameta-analysis.JDermatologTreat2011;22:731–41.
323–36.19LeonardiCL,KimballAB,PappKAetal.Ef?cacyandsafety
9FeldmanS.Aquantitativede?nitionofseverepsoriasisofustekinumab,ahumaninterleukin-12/23monoclonal
foruseinclinicaltrials.JDermatologTreat2004;15:antibody,inpatientswithpsoriasis:76-weekresultsfroma
27–9.randomised,double-blind,placebo-controlledtrial
10PatelRV,ClarkLN,LebwohlM,WeinbergJM.(PHOENIX1).Lancet2008;371:1665–74.
Treatmentsforpsoriasisandtheriskofmalignancy.20PappKA,LangleyRG,LebwohlMetal.Ef?cacyand
JAmAcadDermatol2009;60:1001–17.safetyofustekinumab,ahumaninterleukin-12/23
11ApelM,UebeS,EkiciAetal.Detectionofcopynumbermonoclonalantibody,inpatientswithpsoriasis:52-week
variantsatnewpsoriasislociidenti?edbygenomewideresultsfromarandomised,double-blind,
associationstudies.OralpresentationFC-1.Psoriasis:placebo-controlledtrial(PHOENIX2).Lancet2008;371:
fromGenetoClinic6thInternationalCongress,2011.1675–84.
BrJDermatol2011;165:e1.21PappK,Grif?thsC,GordonKetal.Long-termsafetyof
12ElliottM,BensonJ,BlankMetal.Ustekinumab:lessonsustekinumabinpatientswithmoderate-to-severe
learnedfromtargetinginterleukin-12/23p40inpsoriasis:?nalresultsfrom5yearsoffollow-up.BrJ
immune-mediateddiseases.AnnNYAcadSci2009;Dermatol2013;168:844–54.
1182:97–110.22TsaiTF,HoJC,SongMetal.Ef?cacyandsafetyof
13HaddixAC,TeutschSM,CorsoPS.Preventionustekinumabforthetreatmentofmoderate-to-severe
Effectiveness.AGuidetoDecisionAnalysisandEconomicpsoriasis:aphaseIII,randomized,placebo-controlledtrial
Evaluation.Oxford:OxfordUniversityPress,2003.inTaiwaneseandKoreanpatients(PEARL).JDermatol
14GuentherL,HanC,SzaparyPetal.ImpactofSci2011;63:154–63.
ustekinumabonhealth-relatedqualityoflifeandsexual
a2014BritishAssociationofDermatologistsClinicalandExperimentalDermatology(2014)39,pp696–707707 |
|
